Astellas Pharma (OTCMKTS:ALPMY) Upgraded at Smbc Nikko Sec.

Smbc Nikko Sec. upgraded shares of Astellas Pharma (OTCMKTS:ALPMY) to a hold rating in a research note released on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Four research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Astellas Pharma Stock Performance

OTCMKTS:ALPMY opened at $16.20 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $16.95. The business has a 50 day moving average price of $14.29 and a 200-day moving average price of $12.40.

Astellas Pharma (OTCMKTS:ALPMY) last issued its earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.29 by $0.15. The company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 24.24%. Equities analysts forecast that Astellas Pharma will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).